Skip to content


Secuado, Sycrest (asenapine) is a small molecule pharmaceutical. Asenapine was first approved as Secuado on 2010-09-01. It is used to treat bipolar disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A and D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, 5-hydroxytryptamine receptor 1E, and 5-hydroxytryptamine receptor 1A. Saphris's patent is valid until 2033-07-25 (FDA).
Trade Name Sycrest
Common Name Asenapine
Indication bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
Drug Class Tricyclic compounds
Get full access now